Evotec and Vifor Pharma Sign Major Cooperation Agreement
Development of preclinical candidate in the field of anaemia
Evotec AG announced that it has signed an agreement with Vifor Pharma. Evotec will provide and project manage the discovery activities to identify a preclinical candidate for the treatment of anaemia. Due to confidentiality reasons both companies will not reveal further details about the research project.
The agreement applies Evotec's integrated drug discovery expertise and technologies to progress novel small molecules for the treatment of anaemia from discovery into lead optimisation.
Evotec will use scientists based at both its European and Indian sites covering in vitro biology, medicinal chemistry, in vitro and in vivo pharmacology and the programme will be funded through research funding and success based milestones.
Dr Werner Lanthaler, CEO of Evotec, commented: "This agreement represents a great step forward in our business model, as we are committed to identifying a preclinical candidate within an agreed budget. This will allow us to fully integrate and leverage all of our research sites and scientists to efficiently deliver a preclinical candidate to Vifor Pharma and clearly demonstrates the complete integrated drug discovery capability we have."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
